Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma.
hepatocellular carcinoma
immune checkpoint inhibitor
immune microenvironment
molecular target agent
β-catenin activation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Apr 2023
15 Apr 2023
Historique:
received:
25
02
2023
revised:
09
04
2023
accepted:
13
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Recently, the therapeutic combination of atezolizumab and bevacizumab was widely used to treat advanced hepatocellular carcinoma (HCC). According to recent clinical trials, immune checkpoint inhibitors (ICIs) and molecular target agents are expected to be key therapeutic strategies in the future. Nonetheless, the mechanisms underlying molecular immune responses and immune evasion remain unclear. The tumor immune microenvironment plays a vital role in HCC progression. The infiltration of CD8-positive cells into tumors and the expression of immune checkpoint molecules are key factors in this immune microenvironment. Specifically, Wnt/β catenin pathway activation causes "immune exclusion", associated with poor infiltration of CD8-positive cells. Some clinical studies suggested an association between ICI resistance and β-catenin activation in HCC. Additionally, several subclassifications of the tumor immune microenvironment were proposed. The HCC immune microenvironment can be broadly divided into inflamed class and non-inflamed class, with several subclasses. β-catenin mutations are important factors in immune subclasses; this may be useful when considering therapeutic strategies as β-catenin activation may serve as a biomarker for ICI. Various types of β-catenin modulators were developed. Several kinases may also be involved in the β-catenin pathway. Therefore, combinations of β-catenin modulators, kinase inhibitors, and ICIs may exert synergistic effects.
Identifiants
pubmed: 37190239
pii: cancers15082311
doi: 10.3390/cancers15082311
pmc: PMC10136695
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Cancer Sci. 2020 Nov;111(11):4031-4040
pubmed: 32810311
Cancers (Basel). 2020 Apr 27;12(5):
pubmed: 32349374
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Cell Mol Life Sci. 2020 Mar;77(5):919-935
pubmed: 31312879
Liver Cancer. 2020 Aug;9(4):426-439
pubmed: 32999869
Cancer Cell. 2004 Jan;5(1):91-102
pubmed: 14749129
J Hepatol. 2021 Oct;75(4):865-878
pubmed: 33992698
J Cell Sci. 2009 Dec 15;122(Pt 24):4439-51
pubmed: 19920076
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Nature. 2021 Apr;592(7854):444-449
pubmed: 33762736
PLoS One. 2012;7(4):e35826
pubmed: 22558232
Dev Cell. 2009 Dec;17(6):788-99
pubmed: 20059949
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9304-9
pubmed: 27486244
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Cell Mol Immunol. 2020 Nov;17(11):1163-1179
pubmed: 32963356
Nat Rev Mol Cell Biol. 2009 Jul;10(7):468-77
pubmed: 19536106
Sci Signal. 2014 Mar 18;7(317):ra26
pubmed: 24643799
Cancer Discov. 2016 Jan;6(1):80-95
pubmed: 26701088
EMBO Rep. 2014 Dec;15(12):1254-67
pubmed: 25391905
Cancer Res. 2008 Aug 15;68(16):6779-88
pubmed: 18701503
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Nature. 2009 Oct 1;461(7264):614-20
pubmed: 19759537
Nature. 2005 Dec 8;438(7069):867-72
pubmed: 16341016
Cell Death Dis. 2018 Jul 18;9(8):793
pubmed: 30022048
Signal Transduct Target Ther. 2020 Feb 14;5(1):13
pubmed: 32296025
J Exp Clin Cancer Res. 2019 Jul 18;38(1):316
pubmed: 31319849
Am J Gastroenterol. 2014 Apr;109(4):542-53
pubmed: 24513805
J Cell Sci. 2011 Nov 1;124(Pt 21):3537-44
pubmed: 22083140
Biochem Biophys Res Commun. 2019 Oct 1;517(4):722-728
pubmed: 31395338
J Cell Biol. 2001 Sep 3;154(5):983-93
pubmed: 11524435
FEBS J. 2006 Oct;273(20):4594-602
pubmed: 16965538
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Biol Chem. 2003 Jun 27;278(26):24018-25
pubmed: 12700239
Gut. 2023 Jan;72(1):129-140
pubmed: 35197323
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Cell. 2009 Dec 11;139(6):1056-68
pubmed: 20005801
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Oncoimmunology. 2019 Mar 16;8(5):e1581556
pubmed: 31069145
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Cancer Res. 2002 Apr 1;62(7):2064-71
pubmed: 11929826
Cancer Cell. 2009 Nov 6;16(5):366-8
pubmed: 19878868
Cancer Res. 2014 Sep 15;74(18):5287-300
pubmed: 25056121
Mol Cell. 2004 Aug 27;15(4):511-21
pubmed: 15327768
EMBO J. 2018 Oct 15;37(20):
pubmed: 30217955
Science. 1996 May 17;272(5264):1023-6
pubmed: 8638126
Cell. 2002 Mar 22;108(6):837-47
pubmed: 11955436
Gastroenterology. 2017 Sep;153(3):812-826
pubmed: 28624577
Development. 2011 Oct;138(20):4341-50
pubmed: 21903672
Nat Rev Mol Cell Biol. 2012 Dec;13(12):767-79
pubmed: 23151663
EMBO J. 2003 Feb 3;22(3):494-501
pubmed: 12554650
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
EBioMedicine. 2020 Mar;53:102659
pubmed: 32113157
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172
pubmed: 34764464
PLoS Biol. 2006 Apr;4(4):e115
pubmed: 16602827
Nature. 1999 Jun 24;399(6738):798-802
pubmed: 10391247
Liver Cancer. 2021 Jul;10(4):380-393
pubmed: 34414125
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Mol Cell. 2008 Dec 5;32(5):652-61
pubmed: 19061640
Clin Cancer Res. 2019 Apr 1;25(7):2021-2023
pubmed: 30617138
Biochem Biophys Res Commun. 1999 Dec 9;266(1):28-35
pubmed: 10581160
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7
pubmed: 15314234
Cancer Lett. 2019 May 28;450:132-143
pubmed: 30849480
J Hepatol. 2022 Aug;77(2):410-423
pubmed: 35351523
Hepatology. 2018 Sep;68(3):1025-1041
pubmed: 29603348
Nat Chem Biol. 2010 Nov;6(11):829-36
pubmed: 20890287
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Biochim Biophys Acta. 2012 Feb;1823(2):465-75
pubmed: 22173096
Cancer Res. 2021 Feb 15;81(4):1052-1062
pubmed: 33408116
Nat Rev Clin Oncol. 2015 Jul;12(7):408-24
pubmed: 26054909
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cancer Res. 2018 Jan 1;78(1):15-29
pubmed: 29254998
Nat Cell Biol. 2011 Aug 14;13(9):1070-5
pubmed: 21841791
Clin Transl Gastroenterol. 2020 May;11(5):e00179
pubmed: 32677805
Bioorg Med Chem Lett. 2009 Jul 15;19(14):3825-7
pubmed: 19410457
Development. 2009 Oct;136(19):3205-14
pubmed: 19736321
Cancer Sci. 2018 Jan;109(1):43-53
pubmed: 29034543
Curr Biol. 2006 Nov 21;16(22):2239-44
pubmed: 17113388
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Cancer Sci. 2021 May;112(5):1695-1706
pubmed: 33605517
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Hepatol. 2022 Apr;76(4):883-895
pubmed: 34922977
Genes Dev. 2014 Feb 15;28(4):305-16
pubmed: 24532711
Nature. 2005 Dec 8;438(7069):873-7
pubmed: 16341017
J Hepatol. 2016 May;64(5):1076-1089
pubmed: 26778753
Genes Dev. 2010 Nov 15;24(22):2517-30
pubmed: 21078818
Cold Spring Harb Perspect Biol. 2012 Nov 01;4(11):
pubmed: 23024173